These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11327342)

  • 1. Current therapy of multiple sclerosis.
    Johnson KP; Baringer JR
    Hosp Pract (1995); 2001 Apr; 36(4):21-2, 25-8; discussion 28-9. PubMed ID: 11327342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
    [No Abstract]   [Full Text] [Related]  

  • 3. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate for the treatment of multiple sclerosis.
    Wolinsky JS
    Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
    Kocer B; Nazliel B; Oztas M; Batur HZ
    Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
    [No Abstract]   [Full Text] [Related]  

  • 9. Glatiramer acetate induced hepatotoxicity.
    Subramaniam K; Pavli P; Llewellyn H; Chitturi S
    Curr Drug Saf; 2012 Apr; 7(2):186-8. PubMed ID: 22873505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 11. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory treatment of MS in Slovenia.
    Sega-Jazbec S
    Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
    [No Abstract]   [Full Text] [Related]  

  • 13. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug rationing in the UK.
    Wood P
    Br J Gen Pract; 2002 Nov; 52(484):941-2. PubMed ID: 12434968
    [No Abstract]   [Full Text] [Related]  

  • 15. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 17. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

  • 18. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.
    Hotermans C; Belachew S; Moonen G; Delwaide J
    Mult Scler; 2009 Nov; 15(11):1378-9. PubMed ID: 19965562
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.